Search

Your search keyword '"Senecal JL"' showing total 2 results
Start Over Author "Senecal JL" Topic scleroderma, systemic
2 results on '"Senecal JL"'

1. Centrosome proteins: a major class of autoantigens in scleroderma.

Author

Gavanescu I, Vazquez-Abad D, McCauley J, Senecal JL, and Doxsey S

Subjects
Antigens immunology, Autoantigens genetics, Fluorescent Antibody Technique, Indirect, Humans, Immunoblotting, Recombinant Fusion Proteins immunology, Scleroderma, Systemic diagnosis, Sensitivity and Specificity, Autoantibodies blood, Autoantigens immunology, Centrosome immunology, Scleroderma, Systemic immunology
Abstract

Autoantibodies to intracellular antigens are a hallmark of autoimmune diseases, although their role in disease pathogenesis is unclear. Centrosomes are organelles involved in the organization of the mitotic spindle and they are targets of autoantibodies in systemic sclerosis (SSc). We used recombinant centrosome autoantigens, centrosome-specific antibodies, and immunoassays to demonstrate that a significant proportion of SSc patients exhibited centrosome reactivity. Two centrosome proteins cloned in our laboratory were used to screen 129 SSc sera by Western blotting. The same sera were screened by immunofluorescence using centrosome-specific antibodies to distinguish centrosomes from nuclear speckles commonly stained by SSc sera. Using these criteria, 42.6% of SSc patients were autoreactive to centrosomes, a larger percentage than reacted with all other known SSc autoantigens. Most centrosome-positive sera reacted with both centrosome proteins and half were negative for other routinely assayed SSc autoantibodies. By these criteria, we have identified a novel class of SSc autoreactivity. Only a small percentage of normal individuals and patients with other connective tissue diseases had centrosome reactivity. These results demonstrate that centrosome autoantibodies are a major component of autoreactivity in SSc and thus have potential in disease diagnosis. Centrosome autoantigens may be useful in studying the development of autoantibodies and chronic inflammation in SSc and perhaps other autoimmune diseases.

Published
1999
Full Text
View/download PDF

2. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis

Author

Distler, O, Behrens, F, Pittrow, D, Huscher, D, Denton, Cp, Foeldvari, I, Humbert, M, Matucci Cerinic, M, Nash, P, Opitz, Cf, Rubin, Lj, Seibold, Jr, Furst, De, EPOSS Omeract Group including Ahmadi Simab, K, Albera, Carlo, Bolster, Mb, Brühlmann, P, Burger, C, Chan, K, Chatterjee, S, Clements, P, Confalonieri, M, Csuka, Me, Farber, H, Fessler, B, Foley, R, Frantz, R, Gran, Jt, Highland, K, Hoeper, M, Hsu, V, Inanc, M, Jansa, P, Johnson, S, Kahaleh, B, Kawut, Sm, Keogh, A, Khanna, D, Kähler, Cm, Lang, I, Mahmud, Th, Mandel, J, Mathier, M, Mayes, M, Mchugh, N, Mckown, K, Mclaughlin, V, Medsger TA Jr, Mehta, S, Merkel, Pa, Mubarak, K, Nathan, S, Oudiz, R, Palevsky, H, Park, M, Pope, J, Presberg, K, Ralph, D, Rich, S, Rothfield, N, Rubenfire, M, Scorza, R, Senecal, Jl, Shanahan, J, Silver, R, Staehler, G, Steen, V, Strange, C, Sweiss, N, Taichman, D, Talwar, A, Voskuyl, A, Wigley, F, Williamson, T, Wollheim, F., and University of Zurich

Subjects
Cardiac Catheterization, medicine.medical_specialty, Delphi Technique, Visual analogue scale, Hypertension, Pulmonary, 2745 Rheumatology, Immunology, Delphi method, Placebo-controlled study, Blood Pressure, 610 Medicine & health, Severity of Illness Index, law.invention, Rheumatology, Quality of life, Randomized controlled trial, law, Outcome Assessment, Health Care, Severity of illness, Cluster Analysis, Immunology and Allergy, Medicine, Pharmacology (medical), Randomized Controlled Trials as Topic, Scleroderma, Systemic, business.industry, 10051 Rheumatology Clinic and Institute of Physical Medicine, Clinical trial, Blood pressure, Echocardiography, Exercise Test, Quality of Life, Physical therapy, business
Abstract

Objective. Outcome measures for pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) are only partially validated. The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc. Methods. Sixty-nine PAH-SSc experts (rheumatologists, cardiologists, pulmonologists) rated a list of disease domains and measurement tools in an Internet-based 3-stage Delphi consensus study. In stages 2 and 3, the medians of domains and measurement tools and frequency distributions of ratings, along with requests for re-ratings, were distributed to respondents to provide feedback. A final score of items was identified by means of cluster analysis. Results. The experts judged the following domains and tools as most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure and cardiac function both measured by right heart catheterization and echocardiography, exercise testing measured by 6-minute walking test and oxygen saturation at exercise, severity of dyspnea measured on a visual analog scale, discontinuation of treatment measured by (serious) adverse events, quality of life/activities of daily living measured by the Short Form 36 and Health Assessment Questionnaire disability index, and global state assessed by physician measured by survival. Conclusion. Among experts in PAH-SSc, a core set of outcome measures has been defined for clinical trials by Delphi consensus methods. Although these outcome measures are recommended by this expert group to be used as an interim tool, it will be necessary to formally validate the present measures, as well as potential research measures, in further studies.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results